Physician profile
Steven John Ryder
NPI 1366732851
$7,621.08
in general payments reported to CMS, 2019-2025
29 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $260 · 2021: $959 · 2022: $1,573 · 2023: $1,106 · 2024: $858 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,472 · Travel and Lodging: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.48 |
| Travel and Lodging | $753.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Notal Vision, INC. | $1,679.99 | 2019-2025 | Foresee Home |
| Davol INC. | $982.30 | 2025 | Phasix Mesh |
| Genentech USA, INC. | $720.80 | 2019-2025 | Vabysmo, Susvimo |
| US Retina LLC | $641.28 | 2020-2022 | |
| Abbvie INC. | $505.94 | 2022-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $470.89 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $425.91 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $321.56 | 2020-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $211.72 | 2023-2025 | Izervay |
| Allergan, INC. | $210.90 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $186.30 | 2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Amgen INC. | $155.38 | 2024-2025 | Pavblu, Tepezza |
| Biogen, INC. | $123.74 | 2022-2024 | Byooviz |
| Coherus Oncology, INC. | $123.56 | 2022-2023 | |
| Aerie Pharmaceuticals, INC. | $121.87 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spark Therapeutics, INC. | $97.08 | 2019 | |
| Horizon Therapeutics Plc | $83.38 | 2023 | Tepezza |
| Eyepoint US, INC. | $81.69 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $75.24 | 2022-2025 | Xipere, Visudyne |
| Carl Zeiss Meditec, INC. | $69.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $69.69 | 2019-2021 | |
| Genentech, INC. | $57.24 | 2025 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.71 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $39.64 | 2024 | Xdemvy |
| Rxsight INC | $39.54 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $21.18 | 2020 | |
| Eyevance Pharmaceuticals LLC | $20.70 | 2020 | |
| Mallinckrodt Hospital Products INC. | $19.32 | 2025 | Acthar |
| Rayner Intraocular Lenses Limited | $14.77 | 2025 | Rayone Emv, Rayner Cataract Set 1, Rayone Aspheric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,597.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Ryder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.